Gene

FLT4

fms related receptor tyrosine kinase 4

Explore in graph →CI-GENE-00002046HGNC:3767 ENSG00000037280 NCBI 2324 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT4 Amplification2
Pazopanib	Angiosarcoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID5911 One patient with angiosarcoma was initially treated with sorafenib, an inhibitor of VEGFR2, and developed progressive disease. The patient then received pazopanib, an inhibitor of VEGFR2 and VEGFR3 an… (full text at CIViC) PMID 27160228 · Ravi et al., 2016 · Open in CIViC	civic
〃	Ewing Sarcoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7539 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that respond… (full text at CIViC) PMID 28377484 · Subbiah et al., 2017 · Open in CIViC

Cohorts

Alteration frequency by cohort (159)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved159 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
MYC Family Amplifications in MSK-IMPACT Solid Tumors (MSK, 2026) mycf_msk_2026	unmapped	Ssm	77	3,442	2.2%	69

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.